Zydus Lifesciences Ltd 2019 AR2
The report highlights Cadila Healthcare Limited's financial and operational performance for the fiscal year 2018-2019, emphasizing its focus on innovation in pharmaceuticals, biologics, and vaccines. Key achievements include the completion of Phase II clinical trials for Desidustat and Phase III trials for Rabimabs in India. The company also expanded its consumer wellness portfolio through the acquisition of Heinz India Private Limited. Additionally, the company continued its CSR initiatives through the Ramanbhai Foundation, notably supporting the Zydus Medical College and Hospital at Dahod.
Company: Zydus Lifesciences Ltd
Sector: Health Care
Country: India
Year: 2019
Type: AR2
Pages: 260
Zydus Lifesciences Ltd
Annual Report
The report highlights Cadila Healthcare Limited's financial and operational performance for the fiscal year 2018-2019, emphasizing its focus on innovation in pharmaceuticals, biologics, and vaccines. Key achievements include the completion of Phase II clinical trials for Desidustat and Phase III trials for Rabimabs in India. The company also expanded its consumer wellness portfolio through the acquisition of Heinz India Private Limited. Additionally, the company continued its CSR initiatives through the Ramanbhai Foundation, notably supporting the Zydus Medical College and Hospital at Dahod.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees